Hemophagocytic Lymphohistiocytosis in 2 Patients with Multiple Sclerosis Treated With Alemtuzumab
View / Open Files
Authors
Saarela, Mika
Senthil, Keerthi
Tienari, Pentti
Soilu-hanninen, Merja
Airas, Laura
Saarinen, Jukka
Publication Date
2018-05-01Journal Title
Neurology
Publisher
Wolters Kluwer Health
Volume
90
Issue
18
Pages
849-851
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Saarela, M., Senthil, K., Jones, J., Tienari, P., Soilu-hanninen, M., Airas, L., Coles, A., & et al. (2018). Hemophagocytic Lymphohistiocytosis in 2 Patients with Multiple Sclerosis Treated With Alemtuzumab. Neurology, 90 (18), 849-851. https://doi.org/10.1212/WNL.0000000000005420
Abstract
Alemtuzumab is a highly effective treatment of relapsing-remitting multiple sclerosis (RRMS) with a complex safety profile, including secondary autoimmunity in 40% of patients [1]. We report two cases of hemophagocytic lymphohistiocytosis (HLH) in patients after alemtuzumab treatment of RRMS. This hyperinflammatory syndrome consists of fever, lymphadenopathy, pancytopenia, liver abnormalities, hyperferritinemia, raised soluble interleukin 2 (IL2) receptor and hemophagocytosis; it may be secondary to malignancies, autoimmune diseases, or infections [2]. Table 1 summarizes the diagnostic criteria for secondary HLH.
Sponsorship
Wellcome Trust (105924/Z/14/Z)
Wellcome Trust (105924/Z/14/A)
Wellcome Trust (105924/Z/14/Z)
Embargo Lift Date
2100-01-01
Identifiers
External DOI: https://doi.org/10.1212/WNL.0000000000005420
This record's URL: https://www.repository.cam.ac.uk/handle/1810/275314
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.